Mumbai-based Glenmark Pharmaceuticals has also introduced a generic drug of Empagliflozin under the brand name Glempa, along with its fixed-dose combinations Glempa-L and Glempa-M. Alok Malik, ...

Mumbai-based Glenmark Pharmaceuticals has also introduced a generic drug of Empagliflozin under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations Glempa-L ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Glenmark Pharmaceuticals also launched the drug and said its version of the SGLT2 inhibitor product was being launched as Glempa, and in multiple strengths - Empagliflozin 10/25 mg, besides fixed-dose ...

Glenmark launched empagliflozin under the brand name Glempa, along with fixed-dose combinations. The company price 10mg dosage at Rs 11 per tablet and 25 mg at 14 per tablet. "The launch of Glempa ...

The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations ...

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M ...

The New Zealand Government is set to introduce significant changes to the country’s tax rules, aiming to foster investment and attract skilled professionals, according to Revenue Minister Simon Watts.

Glenmark Pharmaceuticals has introduced Glempa, a medication designed for glycemic control and weight-loss in type 2 diabetes patients. The drug, an SGLT2 inhibitor, aims to improve cardiovascular ...

The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M ...